Related Experiment Video
Updated: Aug 26, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic
D Korkolis1, A Ardavanis, J Yotis
1Second Department of Surgery, Hellenic Anticancer Institute, St. Savvas Hospital, Athens, Greece.
Purpose:
To evaluate the relationship between HER-2/neu overexpression and standard as well as investigational prognostic factors in Greek females with invasive breast carcinoma.
Materials And Methods:
Paraffin-embedded tumor sections from 128 consecutive primary breast cancer patients were screened for HER-2/neu oncoprotein (p185) overexpression by immunohistochemistry using the polyclonal antibody A 0485. The relationship between HER-2/neu staining and other established markers of prognosis were examined using both a univariate and a multivariate analysis.
Results:
HER-2/neu overexpression was detected in 46.1% of tumors. No statistical correlation was found between HER-2/neu and age, tumor diameter, histologic type, nodal status, tumor grade, stage, estrogen and progesterone receptor status or cathepsin-D. A significant correlation was noted between HER-2/neu and p53 overexpression in the total sample (p=0.014) as well as in node-positive patients (p=0.026). In those groups, HER-2/neu and p53 co-expression was found in 19.5% and 21.6% of cases, respectively. In node-negative patients, HER-2/neu overexpression did not correlate with any other marker.
Conclusion:
HER-2/neu overexpression seemed to correlate only with p53 oncoprotein.
